Scientech Research LLC Has $1.15 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Scientech Research LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 93.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,785 shares of the company's stock after purchasing an additional 1,345 shares during the quarter. Scientech Research LLC's holdings in IDEXX Laboratories were worth $1,151,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IDXX. Miracle Mile Advisors LLC acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $201,000. Oak Thistle LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth approximately $426,000. Fifth Third Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 17.8% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 984 shares of the company's stock worth $407,000 after purchasing an additional 149 shares in the last quarter. Outlook Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 20.5% in the fourth quarter. Outlook Wealth Advisors LLC now owns 852 shares of the company's stock worth $352,000 after purchasing an additional 145 shares in the last quarter. Finally, Gateway Investment Advisers LLC lifted its position in shares of IDEXX Laboratories by 11.5% in the fourth quarter. Gateway Investment Advisers LLC now owns 12,349 shares of the company's stock worth $5,106,000 after purchasing an additional 1,274 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on IDXX. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Finally, Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded down $4.52 during midday trading on Tuesday, hitting $517.16. The company had a trading volume of 606,894 shares, compared to its average volume of 649,204. The business's 50 day simple moving average is $433.47 and its two-hundred day simple moving average is $432.18. The stock has a market cap of $41.59 billion, a PE ratio of 48.47, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.71 earnings per share. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.